查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1832213

抗凝血酶市场按类型、来源、剂型、治疗用途和最终用户划分－2025-2032 年全球预测

Antithrombin Market by Type, Source, Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年抗凝血酶市场将成长至 10.9515 亿美元，复合年增长率为 4.83%。

主要市场统计数据
基准年2024年 7.5049亿美元
预计2025年 7.8532亿美元
预测年份：2032年 10.9515亿美元
复合年增长率（%） 4.83%

全面介绍抗凝血酶生物学、临床相关性、诊断复杂性、影响现代凝血疗法的治疗意义。

抗凝血酶作为一种丝胺酸蛋白酶抑制剂，能够调节凝血酶和Xa因子的活性，在止血过程中发挥核心作用。近几十年来，其临床和研究意义显着扩展。临床医师在各种情况下都会遇到抗凝血酶缺乏症，从遗传性终身疾病到严重疾病的后天性缺陷，进而影响治疗决策和风险管理策略。从转化科学的角度来看，抗凝血酶既是重要的生物标记物，也是潜在的治疗药物，而血浆来源抗凝血酶和重组抗凝血酶之间的区别带来了安全性、免疫抗原性和生产的考虑。

随着法律规范的不断发展，诊断演算法正在将抗凝血酶活性检测与基因和临床数据相结合，以完善病例定义并指导替代疗法。此外，製剂和给药技术的进步也开始改变抗凝血酶产品的储存、给药方式以及在急性和慢性照护中的应用。综上所述，这些因素使抗凝血酶成为实验室研究、临床应用和治疗方法创新之间的纽带，并对医院、诊断实验室和寻求优化患者预后的研究项目产生深远影响。

不断发展的科学、监管和临床动态正在改变抗凝血酶产品的开发、诊断方法和治疗模式

在科学进步、监管压力和临床实践不断发展的推动下，抗凝血酶领域正在经历一场变革。重组技术的创新正在减少对血浆来源的依赖，并引发了围绕生产扩充性、产品一致性和批次间差异性的讨论。同时，检测准确性的提高和照护现场技术的进步使得能够早期准确地识别抗凝血酶缺乏症，从而影响高风险环境中的预防策略和急性管理。

同时，对抗凝血酶在发炎和内皮生物学中的作用的更清晰理解正在重塑治疗模式，鼓励人们考虑超越经典凝血障碍的更广泛适应症。监管机构对血浆来源和病原体惰性方法的审查，推动了人们对可追溯性和安全性的期望，而医疗保健系统则将供应链弹性和低温运输优化放在首位。因此，生产、临床和设施领域的相关人员正在重新调整优先事项，以平衡疗效、安全性和营运可行性，这些转变将影响未来的采购、临床指南和研发蓝图。

评估 2025 年美国关税如何重新调整抗凝血酶供应链中的供应链、采购重点和国内生产策略

美国2025年实施的关税政策为抗凝血酶生态系统带来了新的复杂性，影响了整个价值链的筹资策略和供应商选择。进口关税正在影响製造商在本地化生产、与填充厂合作以及供应链路线规划方面的决策，以降低增加的到岸成本。医院和大型综合分销网络正在透过审查供应商合约、强调多方采购安排和紧急库存来应对，以维持临床的连续性。

在下游领域，关税上调加速了关于国内生产能力以及在境内扩大重组生产规模可行性的讨论。同时，诊断和研究实验室也考虑了与替代采购相关的营运权衡，例如增加的前置作业时间和低温运输冗余的需求。虽然采购团队承受了眼前的行政负担，但这种政策环境也鼓励了对本地製造伙伴关係和流程优化计画的策略性投资，旨在减轻未来外部政策变化的影响。展望未来，相关人员越来越重视有韧性、透明且适应性强的供应框架，以管理贸易政策对抗抗凝血酵素可用性和可靠性的连锁反应。

详细的细分洞察，将产品异构体、采购途径、配方选择、治疗用途和最终用户需求与临床采用和开发重点联繫起来

细分主导分析揭示了不同的产品和最终用户载体如何影响抗凝血酶的临床效用、开发选择和采用动态。按类型分析时，α和β异构体之间的区别异构体独特的生化特性和生理作用，可以为诊断解读和治疗靶点提供信息，从而影响检测方法的选择和治疗方案的製定。按来源分析，人类血浆来源抗凝血酶和重组抗凝血酶之间的对比凸显了供体依赖性、病原体安全性和生产控制方面的权衡，这些权衡通常与机构采购政策和临床医生偏好相互交叉。

在考虑製剂形式，液体和粉末配方之间的差异对于临床储存、保质期和重建工作流程非常重要；这些属性决定了产品如何纳入输液室和急救方案。注射剂和口服混悬液之间的差异决定了给药途径和患者依从性，尤其是在门诊和家庭输液环境中。抗凝血酶的治疗用途包括后天性缺陷、急性胰臟炎、先天性缺陷、瀰漫性血管内凝血、肝病和与败血症相关的凝血障碍，每种用途都有其独特的临床终点、监测需求和证据层次。最后，门诊手术中心、诊所、诊断实验室、医院和研究机构之间的最终用户细分凸显了不同医疗环境中采用该药物的不同驱动因素：医院强调急性使用和密切监测，诊断实验室优先考虑检测可靠性，研究机构强调机制研究和转化验证。

全面的区域观点，说明美洲、欧洲、中东和非洲以及亚太地区的趋势将如何影响抗凝血酶的生产、监管和临床获取

区域动态对抗凝血酶的生产、监管和部署方式有着重大影响，因此了解地理差异对于策略规划至关重要。在美洲，临床网路和医院系统优先考虑快速获得急性护理，并通常维持复杂的采购通讯协定以平衡价格和供应连续性，而区域法规结构则强调捐赠者的安全和生物製药的可追溯性。在欧洲、中东和非洲，监管的多样性和多样化的医疗保健基础设施导致了不同的获取和采用模式，一些市场优先考虑集中采购，而另一些市场则依赖区域伙伴关係关係进行供应和低温运输物流。

在全部区域，生物技术製造能力的投资不断增加，临床研究也日益加强，这正在重塑供应商的布局，并增加重组产品的选择。此外，多个司法管辖区内医疗体系的转型正在提升诊断能力，以改善抗凝血酶异常的检测，并为各种治疗应用提供证据支持。综上所述，这些全球趋势表明，产品策略、监管参与和分销模式必须根据区域优先事项量身定制，跨境合作和技术转移仍将是改善全球可及性和临床疗效的重要槓桿。

公司层面的关键洞察：製造商​​、生物技术创新者和专业合作伙伴如何透过製造、监管策略和临床合作实现差异化

抗凝血酶的竞争与合作格局由成熟的生技药品製造商、新兴的生物技术公司以及专业的受託製造厂商组成，每家公司都拥有独特的能力。一些公司强调血浆衍生专业知识和捐赠者安全系统，而其他公司则大力投资重组表达平台和製程增强技术，以提高产量并降低差异性。临床研究团队与製造商之间的策略联盟正变得越来越普遍，这使得他们能够加快新适应症的证据生成，并改善上市后监测框架。

此外，与专业物流供应商和诊断公司合作有助于优化低温运输完整性和检测标准化，从而支援更安全、更可靠的产品部署。竞争差异化越来越依赖生产稳健性、法规生命週期管理以及为临床试验客户提供全面技术支援的能力。随着相关人员追求更广泛的临床检验和标籤扩展可能性，智慧财产权策略、平台技术和生产布局决策将继续决定哪些公司能够引领创新，以及哪些合作联盟能够提供集体优势。

为高阶主管领导层提供切实可行的建议，以加强整个抗凝血酶价值链的製造弹性、监管参与和临床采用策略

产业领导者应采取一系列切实可行、影响深远的行动，以应对科学发展、政策转变和不断变化的临床需求。首先，投资于灵活的生产策略，将重组生产能力与地理分布的填充能力相结合，以减少对单一来源的依赖，并适应区域采购偏好。其次，优先考虑可靠的分析方法和检测方法的外部验证，以提高诊断信心，并支持不同医疗机构的临床应用。第三，积极与监管机构合作，在可追溯性、病原体安全方法和上市后证据生成方面达成一致，从而促进产品接受度和长期安全监测。

此外，我们将与医院系统、诊断实验室和研究机构建立策略伙伴关係，共同设计基于真实世界的实证研究，以证明抗凝血酶在潜在治疗应用中的临床价值。我们将透过多元化物流合作伙伴和投资低温运输来增强供应链的弹性，同时探索能够根据政策和需求变化快速扩展的製造外包关係。最后，我们将透过针对临床医生和采购团队的有针对性的培训来加强商业准备，这些培训旨在阐明产品差异化、管理工作流程以及供应商和配方选择对患者管理的影响。

阐明一种混合方法研究方法，将文献综合、监管调查、技术评估和专家访谈结合起来，为实际决策提供信息

本次分析综合了同行评审文献、监管文件、临床试验註册中心、产品标籤、生产白皮书以及对临床医生、供应链专业人员和行业专家的结构化访谈的证据。主要的定性输入包括测试方法审查以及与药品附加檔的三角检验，以确保全面了解产品特性和临床工作流程。为了保持调查方法的严谨性，我们采用了标准化的临床试验评估标准、交叉引用了主要司法管辖区的监管指南，并记录了每项关键声明的资料来源。

重组和血浆衍生产品的技术评估尽可能以工艺描述和专家关于扩充性和品管的评论为支撑。透过情境分析和相关人员访谈评估供应链和政策影响，以了解营运现状和适应策略。自始至终，该方法都强调透明度、可重复性和对决策者的实际相关性，并在证据不断发展或临床共识尚未达成的情况下提出警告。这种混合方法框架确保结论和建议基于多种证据来源，并根据实际营运限制进行量身定制。

结论摘要强调了推动抗凝血酶科学和临床应用所需的科学创新、营运弹性和策略参与之间的相互作用

总而言之，抗凝血酶是一个多方面的临床和技术领域，其中科学的细微差别、製造选择和医疗保健服务的现实情况相互交织。重组技术的发展、精细诊断以及对区域製造的投资正在改变产品的开发、监管和消费方式。同时，由于异构体、来源、剂型、治疗用途和最终用户情况的细分化，凸显了製定精细定制的产品和商业化策略的必要性。

要在这种环境下取得成功，相关人员必须在创新与营运信誉之间取得平衡，儘早与监管机构和临床意见领袖沟通，并使生产布局与区域可及性需求保持一致。严谨的证据生成、策略伙伴关係以及灵活的物流规划相结合，将使企业能够有效满足临床需求，同时推动抗凝血酶治疗和诊断科学的发展。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 重组抗凝血酶治疗对降低心血管手术术后血栓症形成风险的影响
  • 评估新兴医疗保健市场重组抗凝血酶产品的全球准入壁垒
  • 评估缺陷筛检计画对医疗资源利用的经济影响
  • 加护治疗和急诊室采用照护现场活动测量的趋势
  • 重组抗凝血酶药物跨国临床试验的监管协调挑战
  • SARS-CoV-2 诱发的凝血病对治疗需求和定价策略的影响
  • 整合药物基因组学数据以优化血栓症高风险患者的替代剂量
  • 长期安全性和有效性数据将塑造投资者对下一代生物相似药的信心

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 抗凝血酶市场（按类型）

  • 阿尔法
  • 测试版

9. 抗凝血酶市场（依来源）

  • 人体血浆
  • 重组

第 10 章抗凝血酶市场（依形式）

  • 液体
  • 粉末

第 11 章：抗凝血酶市场（按剂型）

  • 注射
  • 口服悬浮液

第 12 章：抗凝血酶市场（依治疗应用）

  • 后天缺陷
  • 急性胰臟炎
  • 出生缺陷
  • 瀰漫性血管内凝血
  • 肝病
  • 脓毒症相关凝血病

第 13 章。抗凝血酶市场（按最终用户）

  • 门诊手术中心
  • 诊所
  • 诊断实验室
  • 医院
  • 研究机构

第 14 章。按地区分類的抗凝血酶市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章抗凝血酶市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章。各国抗凝血酶市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Baxter International Inc.
    • Bio-Techne Corporation
    • Biocon Ltd.
    • Boehringer Ingelheim Pharma GmbH & Co. KG
    • China Biologic Products, Inc.
    • Diapharma Group, Inc.
    • European Medicines Agency
    • F. Hoffmann-La Roche Ltd
    • Genesis BioPharma Services
    • Grifols, SA
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Lee Biosolutions, Inc.
    • LFB USA, Inc.
    • Merck KGaA
    • Novartis AG
    • Octapharma AG
    • Pfizer Inc.
Product Code: MRR-4358BACA8223

The Antithrombin Market is projected to grow by USD 1,095.15 million at a CAGR of 4.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 750.49 million
Estimated Year [2025] USD 785.32 million
Forecast Year [2032] USD 1,095.15 million
CAGR (%) 4.83%

Comprehensive introduction to antithrombin biology, clinical relevance, diagnostic complexity, and therapeutic implications shaping contemporary coagulation care

Antithrombin occupies a central role in hemostasis as a serine protease inhibitor that modulates thrombin and factor Xa activity, and its clinical and research significance has expanded markedly over recent decades. Clinicians encounter antithrombin deficiency across a spectrum that ranges from inherited, lifelong disorders to acquired deficiencies in critical illness, which in turn influence therapeutic decision-making and risk management strategies. From a translational science perspective, antithrombin is consequential both as a biomarker and as a therapeutic agent candidate, with distinctions between plasma-derived and recombinant sources shaping safety, immunogenicity, and manufacturing considerations.

As regulatory frameworks evolve, diagnostic algorithms increasingly integrate antithrombin activity assays with genetic and clinical data to refine case definitions and guide replacement therapy. Furthermore, advances in formulation science and delivery modalities have begun to change how antithrombin products are stored, administered, and integrated into acute and chronic care pathways. Taken together, these elements establish antithrombin as a nexus point between laboratory investigation, bedside practice, and therapeutic innovation, with downstream implications for hospitals, diagnostic laboratories, and research programs seeking to optimize patient outcomes.

Evolving scientific, regulatory, and clinical dynamics that are transforming antithrombin product development, diagnostic approaches, and care delivery models

The landscape surrounding antithrombin is undergoing transformative shifts driven by scientific progress, regulatory pressure, and evolving clinical practice. Innovations in recombinant technology have reduced reliance on plasma-derived sources and have catalyzed discussions about manufacturing scalability, product consistency, and batch-to-batch variability. Concurrently, improvements in assay precision and point-of-care diagnostics are enabling earlier and more accurate identification of antithrombin insufficiency, which affects both prophylactic strategies and acute management in high-risk settings.

In parallel, therapeutic paradigms are being reshaped by a clearer understanding of antithrombin's role in inflammation and endothelial biology, prompting investigation into broader indications beyond classical coagulation disorders. Regulatory scrutiny related to plasma sourcing and pathogen inactivation methods has raised expectations for traceability and safety, while health systems emphasize supply chain resilience and cold chain optimization. As a result, stakeholders across production, clinical, and institutional domains are recalibrating priorities to balance efficacy, safety, and operational feasibility, and these shifts will influence procurement, clinical guidelines, and R&D roadmaps going forward.

Assessment of how the 2025 United States tariff measures recalibrated supply chains, procurement priorities, and domestic production strategies in the antithrombin supply network

United States tariff policies implemented in 2025 have introduced a new layer of complexity for the antithrombin ecosystem, affecting procurement strategies and supplier selection across the value chain. The import tariffs have influenced manufacturer decisions regarding localization of production, partnerships for fill-and-finish operations, and supply chain routing to mitigate incremental landed costs. Hospitals and large integrated delivery networks have responded by revisiting supplier contracts, emphasizing multi-sourcing arrangements and contingency inventories to preserve clinical continuity.

In downstream terms, the tariffs have accelerated conversations about domestic capacity and the feasibility of scaling recombinant production within national borders. Simultaneously, diagnostic laboratories and research institutes have weighed the operational trade-offs associated with alternative sourcing, including increased lead times and the potential need for cold chain redundancies. Although procurement teams navigated near-term administrative burdens, the policy environment also catalyzed strategic investments in local manufacturing partnerships and process optimization initiatives aimed at reducing exposure to future external policy shifts. Looking ahead, stakeholders are increasingly prioritizing resilience, transparency, and adaptive supply frameworks to manage the ripple effects of trade policy on antithrombin accessibility and reliability.

Detailed segmentation insights linking product isoforms, sourcing routes, formulation choices, therapeutic uses, and end-user needs to clinical adoption and development priorities

Segmentation-driven analysis reveals how different product and end-user vectors shape clinical utility, development choices, and adoption dynamics for antithrombin. When examined by type, the distinctions between alpha and beta isoforms inform diagnostic interpretation and therapeutic targeting because biochemical properties and physiological roles vary, which can influence assay selection and treatment tailoring. By source, contrasts between human plasma-derived and recombinant antithrombin highlight trade-offs in donor-dependence, pathogen safety, and manufacturing control, and these factors frequently intersect with institutional procurement policies and clinician preferences.

Considering form factors, the distinctions between liquid and powder formulations matter for storage, shelf life, and reconstitution workflows in clinical settings, and these attributes determine how products are integrated into infusion suites and emergency protocols. Dosage form differentiation between injectable preparations and oral suspensions shapes administration pathways and patient adherence considerations, particularly in ambulatory care and home infusion contexts. Across therapeutic applications, antithrombin is applied in acquired deficiency, acute pancreatitis, congenital deficiency, disseminated intravascular coagulation, liver disease, and sepsis associated coagulopathy, each presenting unique clinical endpoints, monitoring demands, and evidence hierarchies. Finally, end-user segmentation encompassing ambulatory surgical centers, clinics, diagnostic laboratories, hospitals, and research institutes underscores that adoption drivers differ by care setting, with hospitals emphasizing acute use and intensive monitoring, diagnostic laboratories prioritizing assay reliability, and research institutes concentrating on mechanistic studies and translational validation.

Comprehensive regional perspective explaining how Americas, Europe Middle East & Africa, and Asia-Pacific trends influence production, regulation, and clinical access for antithrombin

Regional dynamics exert a powerful influence on how antithrombin is produced, regulated, and deployed, and understanding geographic nuances is essential for strategic planning. In the Americas, clinical networks and hospital systems often prioritize rapid access to acute care therapies and maintain complex procurement protocols that balance price with supply continuity, while regional regulatory frameworks emphasize donor safety and biologic traceability. In Europe, Middle East & Africa, regulatory heterogeneity and variable healthcare infrastructures create a spectrum of access and adoption patterns, with some markets emphasizing centralized procurement and others relying on local partnerships to manage supply and cold chain logistics.

Across the Asia-Pacific region, rising investment in biotechnology manufacturing capacity and growing clinical research activity are reshaping supplier footprints and increasing the availability of recombinant options. Transitional healthcare systems in multiple jurisdictions are also expanding diagnostic capabilities, which improves detection of antithrombin abnormalities and supports evidence generation for diverse therapeutic applications. Taken together, these geographic trends suggest that product strategy, regulatory engagement, and distribution models must be tailored to regional priorities, and that cross-border collaboration and technology transfer will remain important levers for improving availability and clinical outcomes globally.

Key company-level insights describing how manufacturers, biotech innovators, and specialized partners differentiate through manufacturing, regulatory strategy, and clinical collaboration

The competitive and collaborative landscape for antithrombin includes a mix of established biologics manufacturers, emerging biotechnology firms, and specialized contract development and manufacturing organizations, each contributing distinct capabilities. Some players emphasize plasma-derived expertise and donor-safety systems, while others have invested heavily in recombinant expression platforms and process intensification techniques to enhance yield and reduce variability. Strategic alliances between clinical research groups and manufacturers have become more prevalent, enabling accelerated evidence generation for novel indications and improved post-market surveillance frameworks.

In addition, partnerships with specialized logistics providers and diagnostic firms are helping to optimize cold chain integrity and assay standardization, which in turn supports safer and more reliable product deployment. Competitive differentiation increasingly rests on a combination of manufacturing robustness, regulatory lifecycle management, and the ability to supply comprehensive technical support to clinical customers. As stakeholders pursue broader clinical validation and potential label expansions, intellectual property strategies, platform technologies, and manufacturing footprint decisions will continue to shape which companies lead in innovation and where collaborative consortia may offer collective advantages.

Actionable recommendations for executives to enhance manufacturing resilience, regulatory engagement, and clinical adoption strategies across the antithrombin value chain

Industry leaders should adopt a set of pragmatic, high-impact actions to navigate scientific developments, policy shifts, and evolving clinical needs. First, invest in flexible manufacturing strategies that combine recombinant production capabilities with geographically distributed fill-and-finish capacity to reduce single-source exposure and to respond to regional procurement preferences. Second, prioritize robust analytical methods and external validation of assays to improve diagnostic confidence and to support clinical adoption across diverse care settings. Third, engage proactively with regulatory authorities to align on traceability, pathogen-safety approaches, and post-market evidence generation that will facilitate product acceptance and long-term safety monitoring.

Additionally, cultivate strategic partnerships with hospital systems, diagnostic laboratories, and research institutes to co-design real-world evidence generation efforts that demonstrate clinical value across the therapeutic applications where antithrombin may be impactful. Strengthen supply chain resiliency by diversifying logistics partners and investing in cold chain redundancy, while also exploring contract manufacturing relationships that can be scaled quickly in response to policy or demand shifts. Finally, enhance commercial readiness through targeted education for clinicians and procurement teams that clarifies product differentiators, administration workflows, and the implications of source and formulation choices for patient management.

Clear explanation of the mixed-methods research approach integrating literature synthesis, regulatory review, technical assessment, and expert interviews to inform practical decision-making

This analysis synthesizes evidence from peer-reviewed literature, regulatory documents, clinical trial registries, product labelling, manufacturing white papers, and structured interviews with clinicians, supply chain professionals, and industry experts. Primary qualitative inputs were triangulated with laboratory method reviews and formulation dossiers to ensure a comprehensive view of product characteristics and clinical workflows. Methodological rigor was maintained by applying standardized appraisal criteria to clinical studies, cross-referencing regulatory guidance across major jurisdictions, and documenting data provenance for each major assertion.

Where possible, technical assessments of recombinant versus plasma-derived production were corroborated with process descriptions and expert commentary on scalability and quality control. Supply chain and policy impacts were evaluated through scenario analysis and stakeholder interviews to capture operational realities and adaptive strategies. Throughout, the approach emphasized transparency, reproducibility, and practical relevance for decision-makers, and caveats were noted where evidence was evolving or where clinical consensus had not yet been established. This mixed-methods framework ensures that conclusions rest on multiple, corroborative lines of evidence and that recommendations are tailored to real-world operational constraints.

Concluding synthesis emphasizing the interplay of scientific innovation, operational resilience, and strategic engagement necessary to advance antithrombin science and clinical access

In conclusion, antithrombin represents a multifaceted clinical and technological domain where scientific nuance, production choices, and healthcare delivery realities intersect. Ongoing advances in recombinant technologies, diagnostic precision, and regional manufacturing investments are changing how products are developed, regulated, and consumed. Trade policy developments have underscored the importance of supply chain resilience and local capacity, while segmentation across isoform, source, form, dosage form, therapeutic application, and end-user context highlights the need for finely calibrated product and commercialization strategies.

To succeed in this environment, stakeholders must balance innovation with operational reliability, engage early with regulators and clinical opinion leaders, and align manufacturing footprints with regional access imperatives. By combining rigorous evidence generation, strategic partnerships, and adaptive logistics planning, organizations can position themselves to meet clinical demand effectively while also advancing the science of antithrombin therapeutics and diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of recombinant antithrombin therapies on reducing postoperative thrombosis risk in cardiac surgery
  • 5.2. Evaluating global access barriers for recombinant antithrombin products in emerging healthcare markets
  • 5.3. Assessing economic impact of antithrombin deficiency screening programs on healthcare resource utilization
  • 5.4. Adoption trends of point of care antithrombin activity assays in critical care and emergency departments
  • 5.5. Regulatory harmonization challenges for multinational clinical trials involving recombinant antithrombin drugs
  • 5.6. Impact of SARS CoV 2 induced coagulopathy on antithrombin therapy demand and pricing strategies
  • 5.7. Integration of pharmacogenomic data for optimizing antithrombin replacement dosing in high risk thrombosis patients
  • 5.8. Long term safety and efficacy data shaping investor confidence in next generation antithrombin biosimilars

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antithrombin Market, by Type

  • 8.1. Alpha
  • 8.2. Beta

9. Antithrombin Market, by Source

  • 9.1. Human Plasma
  • 9.2. Recombinant

10. Antithrombin Market, by Form

  • 10.1. Liquid
  • 10.2. Powder

11. Antithrombin Market, by Dosage Form

  • 11.1. Injectable
  • 11.2. Oral Suspensions

12. Antithrombin Market, by Therapeutic Application

  • 12.1. Acquired Deficiency
  • 12.2. Acute Pancreatitis
  • 12.3. Congenital Deficiency
  • 12.4. Disseminated Intravascular Coagulation
  • 12.5. Liver Disease
  • 12.6. Sepsis Associated Coagulopathy

13. Antithrombin Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Clinics
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals
  • 13.5. Research Institutes

14. Antithrombin Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antithrombin Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antithrombin Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Baxter International Inc.
    • 17.3.2. Bio-Techne Corporation
    • 17.3.3. Biocon Ltd.
    • 17.3.4. Boehringer Ingelheim Pharma GmbH & Co. KG
    • 17.3.5. China Biologic Products, Inc.
    • 17.3.6. Diapharma Group, Inc.
    • 17.3.7. European Medicines Agency
    • 17.3.8. F. Hoffmann-La Roche Ltd
    • 17.3.9. Genesis BioPharma Services
    • 17.3.10. Grifols, S.A.
    • 17.3.11. Jiangsu Hengrui Medicine Co., Ltd.
    • 17.3.12. Lee Biosolutions, Inc.
    • 17.3.13. LFB USA, Inc.
    • 17.3.14. Merck KGaA
    • 17.3.15. Novartis AG
    • 17.3.16. Octapharma AG
    • 17.3.17. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTITHROMBIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 266. GCC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 267. GCC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 268. GCC ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 269. GCC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 270. GCC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 271. GCC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. GCC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. GCC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 308. G7 ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 309. G7 ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 310. G7 ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 311. G7 ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 312. G7 ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 313. G7 ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. G7 ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. G7 ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. G7 ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 322. NATO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 323. NATO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 324. NATO ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 325. NATO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 326. NATO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 327. NATO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. NATO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. NATO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. NATO ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 339. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 340. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 341. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 342. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 343. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 348. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 349. CANADA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 350. CANADA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 351. CANADA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 352. CANADA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 353. CANADA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 354. CANADA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 355. CANADA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. CANADA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 357. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 359. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 360. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 361. MEXICO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 362. MEXICO ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 363. MEXICO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 364. MEXICO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 365. MEXICO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 366. MEXICO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 367. MEXICO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 368. MEXICO ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 369. BRAZIL ANTITHROMBIN MARKET SIZE, BY TYPE